Trials / Active Not Recruiting
Active Not RecruitingNCT04188548
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3484356 | Administered orally |
| DRUG | Abemaciclib | Administered orally |
| DRUG | Everolimus | Administered orally |
| DRUG | Alpelisib | Administered orally |
| DRUG | Trastuzumab | Administered intravenously |
| DRUG | Aromatase Inhibitor (AI) | Anastrozole or Exemestane or Letrozole administered orally (physician choice) |
| DRUG | Pertuzumab | Administered intravenously |
Timeline
- Start date
- 2019-12-10
- Primary completion
- 2020-06-29
- Completion
- 2027-12-01
- First posted
- 2019-12-06
- Last updated
- 2025-06-04
Locations
74 sites across 8 countries: United States, Australia, Belgium, France, Japan, South Korea, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04188548. Inclusion in this directory is not an endorsement.